NIR stimulus-responsive AstragalosideIV-Indocyanin green liposomes for chemo-photothermal therapy

Xiaowei Wang,Yufen Li,Ji Li,Yaxuan Gu,Lihong Sang,Dongkai Wang
DOI: https://doi.org/10.1016/j.jddst.2020.102257
IF: 5
2021-08-01
Journal of Drug Delivery Science and Technology
Abstract:The combination of multiple therapies could significantly improve the efficiency of treatment for malignant tumors, which has become the trend of cancer research and treatment. Astragaloside IV (AS-IV) is able to enhance the sensitivity of anti-tumor drugs and reduce the adverse reactions, but AS-IV alone is not much powerful lethality to cancer cells. AS-IV and photosensitizer ICG are combined, which contributes to elevate the anti-tumor effect. In this study, we constructed the liposome co-loading with AS-IV and near infrared (NIR) dye ICG for chemo-photothermal therapy of breast cancer. In addition, the anticancer properties of the liposome have been studied <em>in vitro</em> and <em>in vivo</em>. AS-IV/ICG-LPs showed the uniform structure, preferable photothermal response, excellent physiological stability, and photo-responsive drug release behavior. Furthermore, in comparison with individual chemotherapy or PTT, the combinational chemo-PTT therapy of AS-IV/ICG-LPs with NIR laser irradiation synergistically induced apoptosis and death of cancer cells <em>in vitro</em>, and demonstrated synergistic chemo-PTT efficiency <em>in vivo</em> as evidenced by highly efficient tumor tissue ablation. Moreover, the liposome materials of FDA-approved agents provide a safe strategy in the rational design of synergistic combination therapy.<span class="display"><span><ol class="links-for-figure"><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S177322472031546X-fx1_lrg.jpg"><span class="anchor-text">Download : <span class="download-link-title">Download high-res image (258KB)</span></span></a></li><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S177322472031546X-fx1.jpg"><span class="anchor-text">Download : <span class="download-link-title">Download full-size image</span></span></a></li></ol></span></span>
pharmacology & pharmacy
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to improve the effectiveness and safety of malignant tumor treatment. Specifically, the researchers designed a near - infrared (NIR) - stimulated - responsive astragaloside IV - indocyanine green liposome (AS - IV/ICG - LPs) for combined chemotherapy - photothermal treatment of breast cancer. Astragaloside IV (AS - IV) is a natural anticancer drug, which has the ability to enhance the sensitivity of antitumor drugs and reduce side effects, but its lethality to cancer cells is limited when used alone. Indocyanine Green (ICG) is a near - infrared dye and can be used as a photosensitizer for photothermal treatment. By co - encapsulating AS - IV and ICG into liposomes, the researchers aim to utilize the drug - release mechanism triggered by near - infrared laser irradiation to achieve the synergistic effect of chemotherapy and photothermal treatment, thereby killing cancer cells more effectively and reducing the side effects of treatment. The paper mentions that single chemotherapy or photothermal treatment has a certain effect on eliminating primary tumors, but has limited ability to clear metastatic tumor cells. Therefore, combining chemotherapy and photothermal treatment can overcome the limitations of single - therapy and provide a more effective treatment strategy. In addition, by using FDA - approved materials to prepare liposomes, this study also aims to ensure the safety of treatment and the feasibility of clinical application.